The impact of mangiferin from Belamcanda chinensis on experimental colitis in rats

Abstract

BackgroundInflammatory bowel disease (IBD) [including Crohn’s disease (CD) and ulcerative colitis (UC)] constitutes an important clinical problem. The pathogenesis of IBD remains unclear. It is believed that immune dysfunction, inflammatory mediators and oxidative damage play crucial roles in development of IBD. The condition is clinically associated with symptoms ranging from mild to severe during relapses, depending on the affected segment of the gastrointestinal tract. Bloody diarrhea with mucus, abdominal pain, weight loss and anemia are initial symptoms of both CD and UC. Differences between diseases become more evident in time, along with the development of intestinal and extraintestinal complications. Mangiferin (1,3,6,7-tetrahydroxyxanthone-C-2-β-d-glucoside), a natural polyphenol in plants, exerts antioxidant and anti-inflammatory effects making it an interesting option for the treatment of inflammatory pathologies associated with oxidative stress in humans, such as IBD.PurposeThe aim of the current study was to elucidate the impact of mangiferin on colon tissues in 2,4,6-trinitrobenzensulfonic acid (TNBS)-induced colitis in rats.MethodsMangiferin was obtained from Belamcanda chinensis rhizomes by a multistage process. Groups of rats were pre-treated with 10, 30 or 100 mg/kg of mangiferin, or with distilled water administered intragastrically for 16 days. An ethanol solution of TNBS or saline was given rectally on the day 15 of the experiment. The experiment was terminated on the day 17. The colon was removed, cleaned, weighed and examined macro- and microscopically. Determination of tumor necrosis factor α (TNF-α), interleukin 17 (IL-17), malondialdehyde (MDA) levels and superoxide dismutase (SOD) activity were performed spectrophotometrically in homogenates of colon tissues.ResultsRats in the TNBS group developed symptoms of colitis, including: body weight loss, colon mass index increase and damage of intestinal tissues with concomitant increase in TNF-α, IL-17, MDA levels and decreased SOD activity. In non-TNBS-treated rats mangiferin did not cause any changes of studied parameters. Pre-treatment with mangiferin exerted a protective effect, reducing the intensity of damage caused by TNBS. Mangiferin at the doses of 30 and 100 mg/kg reduced the macro- and microscopic damage score and the MDA level in colon tissues. Only at the dose of 100 mg/kg, mangiferin decreased TNF-α and IL-17 concentrations, and SOD activity in colon tissues.ConclusionMangiferin attenuates inflammatory changes of colon tissues in experimental, TNBS-induced colitis in rats. Protective effect exerted by mangiferin depends primarily on its anti-inflammatory activity and secondarily on its antioxidant properties.

Mangiferin Attenuates Murine Lupus Nephritis by Inducing CD4+Foxp3+ Regulatory T Cells via Suppression of mTOR Signaling

“…MG has been shown to exert various biological activities and therapeutic effects, including anti-inflammatory [7], anti-oxidative [8], anti-tumor [9] and anti-diabetic effects [10] as well as regulation of metabolism [11]. Recent studies have demonstrated that MG attenuates inflammation in experimental colitis [12], corrects the imbalance of Th17/Treg cells in mice with TNBSinduced colitis [13] and inhibits macrophage activation. Therefore, we hypothesized that MG may be effective in treating LN via induction of Tregs.…”

Self-nanoemulsfiying drug delivery system of bruceine D: a new approach for anti-ulcerative colitis

“…78 Overproduction of ROS in intestinal mucosal cells induces the immune response, which leads to the injury of intestinal epithelial cells, disruption of integrity of the intestinal barrier, and initiation of the intestinal inflammation. 79 It is involved in anti-inflammation process and cleared by a series of constitutively expressed antioxidant enzymes, such as SOD and GSH-Px. These two enzymes can counteract the overaccumulation of ROS.…”

Pharmacokinetic and metabolomic analyses of Mangiferin calcium salt in rat models of type 2 diabetes and non-alcoholic fatty liver disease

“…[14,15]. It has shown many kinds of biological activities and pharmacological actions such as antioxidative, antidiabetic, hypolipidemic, antiviral, immunomodulatory, anticancer, analgesic and hepatoprotective effects [16][17][18][19][20]. But the characteristic of its low aqueous solubility and low fat solubility can affect the absorption process of drugs in vivo, which leads to a low bioavailability [21,22].…”